BeiGene, Ltd. (BGNE)
- Business Wire
BeiGene to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, February 01, 2023--BeiGene announced that the Company will participate in two upcoming investor conferences.
- Zacks
Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival
Jazz (JAZZ) reports data from a mid-stage study on its investigational bispecific antibody targeting HER2-expressing mGEA. The treatment achieved an overall survival rate of 84% in 18 months.
- Business Wire
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., January 19, 2023--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Bruton’s tyrosine kinase inhibitor (BTKi) BRUKINSA (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
